CARM1 and osteoporosis: The PFK activity test showed that PFK activity decreased in bone samples from patients with osteoporosis (Figure 4c), and in mc3t1‐e1 and RAW264.7 cells, the regulation of PFK activity by CARM1 could be reversed by MK2206 (an AKT inhibitor) and Compound C (an AMPK inhibitor), respectively (Figure 4d).